DL-Laudanosine

SKU: orb1299152

Description

DL-Laudanosine is a known metabolite formed from the neuromuscular blocking agents atracurium and cisatracurium. It is utilized in pharmacological research to study its potential central nervous system effects and pharmacokinetics in both in vitro and in vivo experimental models.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1699-51-0
• MW: 357.44
• Purity: 98.45% (May vary between batches)
• Formula: C₂₁H₂₇NO₄
• SMILES: COc1ccc(CC2N(C)CCc3cc(OC)c(OC)cc23)cc1OC
• Target: Drug Metabolite
• Solubility: DMSO:11 mg/mL (30.77 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.6 mM)

Bioactivity

• In Vivo:
  laudanosine, a metabolite of atracurium and a central nervous system stimulant, might increase the minimum alveolar concentration (MAC) of halothane. These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1. Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1. The control value for MAC of halothane was 1.08 +/- 0.28%. At the lowest steady state plasma laudanosine concentration, MAC did not significantly differ from control (MAC = 1.15 +/- 0.23%, P less than 0.1). However, at 457 and 873 ng . ml-1, laudanosine significantly increased the MAC of halothane by 23% and 30%, respectively. Infusion with saline in two additional rabbits did not affect MAC. Therefore, at the plasma concentrations of laudanosine found in humans after administration of atracurium, laudanosine increased the MAC of halothane in rabbits.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DLLaudanosine, DL-Laudanosine, DL Laudanosine, DrugMetabolite, Drug Metabolite

Compound Identifiers

PubChem CID

15548